Abstract-The authors performed nerve conduction studies in nine PARK2 and eight idiopathic Parkinson disease patients and found a significant reduction of sural sensory nerve action potential (SNAP) amplitude in eight PARK2 patients who mostly remained asymptomatic. These data suggest that sensory axonal neuropathy may be a common clinical feature of PARK2 and a reduced amplitude of sural SNAP could be a diagnostic indicator of PARK2. Numbness, tingling, burning, and pain are common sensory symptoms of Parkinson disease (PD). 1 Several lines of evidence (e.g., the lack of objective sensory loss, the normal nerve conduction study [NCS], 1 the high occurrence on levodopa-off period, and the drastic improvement of pallidal deep brain stimulation) suggest that these sensory symptoms are not of peripheral but of CNS origin. However, 11 of 29 patients with juvenile parkinsonism of unknown etiology showed abnormal NCS in peroneal motor or sural sensory nerves.
1
the high occurrence on levodopa-off period, and the drastic improvement of pallidal deep brain stimulation) suggest that these sensory symptoms are not of peripheral but of CNS origin. However, 11 of 29 patients with juvenile parkinsonism of unknown etiology showed abnormal NCS in peroneal motor or sural sensory nerves. 2 We investigated two autosomal recessive juvenile parkinsonism (PARK2) patients complaining of a tingling sensation with objective sensory loss in the foot (Patients 1, 2 in the table). Based on reduced sural sensory nerve action potential (SNAP) amplitude in these patients, we hypothesized that a mutation of the PARK2 causative gene, Parkin, 3 results in sensory axonal neuropathy. We investigate this hypothesis by examining NCSs in a series of PARK2 and idiopathic PD patients, together with the expression analysis of the Parkin gene in the peripheral nervous system.
Methods. We performed this study in patients under the age of 60 years, because sural SNAP amplitude reduces with aging, and is sometimes absent even in normal subjects over the age of 70 years. 4, 5 Diagnosis of PARK2 was confirmed by DNA analysis using exonic PCR amplification of the Parkin gene as described previously.
3 All PARK2 or idiopathic PD patients were interviewed to determine whether they were experiencing sensory symptoms. Those patients with other causes of neuropathy (e.g., medications including amantadine, exposure to toxins, diabetes mellitus, uremia, hypothyroidism, pernicious anemia, vitamin B6 deficiency, alcohol abuse, syphilis, gammopathy, malignancy, collagen vascular disease) as determined by laboratory testing or medical consultation were excluded from this study. Patients with obesity or leg swelling were also excluded. Seventeen patients with PARK2 or idiopathic PD were enrolled in this study. Two patients, who were clinically diagnosed with idiopathic PD, turned out to have sporadic PARK2 by DNA analysis.
NCS was performed on the median motor and sensory, the ulnar motor and sensory, the tibial motor, the peroneal motor, and the sural sensory nerves using standard methods described previously. 4, 5 For sural NCS, signal averaging of 20 to 50 responses was used. Peak-to-peak amplitude was used for the amplitude measurement and nerve conduction velocity (NCV) was calculated using the onset latency. 4, 5 Age-and sex-matched normal control subjects (20 men, 50.2 Ϯ 5.3 years old; 20 women, 42.0 Ϯ 5.1 years old) were used to determine the standard value of the sural SNAP amplitude, and logarithmic values were used to obtain a normal distribution. The value corresponding to the mean minus 2.5 standard deviations was used as the lower limit of the normal value (7.2 V for men, 5.1 V for women).
Total RNA was extracted from autopsied tissues, including human cerebrum, dorsal root ganglia (DRG), sural nerve, and thoracic sympathetic ganglia. Parkin gene expression was examined by semiquantitative RT-PCR and northern blotting according to the methods as described. Results. Clinical and electrophysiologic findings of nine PARK2 patients are summarized in the top section of the table. The mean age of the PARK2 patients was 49.6 Ϯ 6.5 years (four men, 53.3 Ϯ 4.6 years; five women, 46.6 Ϯ 6.6 years). Seven patients (1, 2, 5 through 9) had PD family history and unique symptoms of PARK2, sleep benefit, levodopa-induced dyskinesia, wearing-off phenomenon, and foot dystonia. [6] [7] [8] Among two patients (1, 2) complaining of foot dysesthesia, one (no. 2) had objective sensory loss of all modality in the foot and another (no. 1) had decreased vibration sense and absence of Achilles tendon reflex in the foot. Six patients had absence or decreased vibration sense in foot. Eight of nine PARK2 patients showed significant reduction of sural SNAP amplitude, but normal NCS findings in all other tested nerves. Of note, two patients (3, 4) with reduced sural SNAP amplitude having neither family history nor unique symptoms of PARK2 were clinically diagnosed with idiopathic PD. However, DNA analysis eventually revealed that they had sporadic PARK2.
Findings of eight idiopathic PD patients are summarized in the lower section of the table. The mean age of eight PD patients was 54.6 Ϯ 3.3 years (four men, 55.3 Ϯ 3.3 years; four women, 54.0 Ϯ 3.7 years). Two patients (10, 11) had dysesthesia-like sensations in the foot without objective sensory loss during the levodopa-off period. In sharp contrast to PARK2 patients, all eight patients with PD showed normal sural SNAP amplitude. There was no patient who showed slow NCV in PARK2 and PD.
The values of sural SNAP amplitude of each subject were plotted in figure 1 . The frequency of reduced sural SNAP amplitude below normal lower limit in PARK2 patients was significantly (p Ͻ 0.01, Fisher's exact Test) higher than that in patients with PD. The mean value of sural SNAP amplitude was significantly (p Ͻ 0.01, MannWhitney U test) reduced in PARK2 patients, compared with patients with PD.
Semi-quantitative RT-PCR and northern blot analysis demonstrated that Parkin gene expression was markedly higher in the DRG and cerebrum than in the sural nerve, and expression was far less abundant in the thoracic sympathetic ganglia (figure 2).
Discussion. The present study showed that nearly all PARK2 patients have reduced amplitude of sural SNAP, suggesting that sensory axonal neuropathy may be a common clinical feature of PARK2. Only five PARK2 patients associated with neuropathy have been reported so far.
7-10 Therefore peripheral neuropathy has been believed to be an atypical presentation of PARK2. [7] [8] [9] [10] In our series of PARK2, only two patients showed subjective sensory symptoms. However, eight of nine patients exhibited marked reductions in the sural SNAP amplitude, even in the absence of sensory symptoms. In sharp contrast, patients with idiopathic PD showed normal results even in the presence of sensory symptoms, which is consistent with previous NCS data. 1 Of note, two patients with a presumptive diagnosis of idiopathic PD (nos. 3, 4) who showed a reduced SNAP amplitude were subsequently diagnosed with PARK2 as a result of DNA analysis. These cases should be classified as sporadic PARK2. Thus, our NCS data strongly suggest that reduced sural SNAP amplitude could distinguish PARK2 from idiopathic PD and that asymptomatic sensory axonal neuropathy is not an atypical but common clinical feature of PARK2 patients. Reduced sural SNAP amplitude in patients with PD under 60 years may be a diagnostic indicator of Parkin mutations. It is important to investigate the sural SNAP amplitude in asymptomatic family members in PARK2 pedigrees to confirm the segregation of sensory neuropathy with Parkin mutations in future study. Interestingly, Parkin gene expression was abundant in DRG, which suggests that parkin may play an important role in maintaining normal integrity of the sensory nervous system. In contrast, Parkin mRNA is relatively sparse in sympathetic ganglia. This differential distribution of Parkin mRNA in the peripheral nervous system well correlates with clinical manifestations of PARK2; sensory neuropathy is common, whereas autonomic dysfunction is quite rare. 6, 7 Further studies to define the molecular mechanism underlying sensory neuropathy in PARK2 patients would be of benefit.
Table Clinical and electrophysiologic findings of PARK2 (Patients 1 through 9) or Parkinson disease (PD) (Patients 10 through 17) patients

